(SENS) Senseonics Holdings, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SENS) Senseonics Holdings, Inc. Complete Analysis Pack
Senseonics Business Model Canvas: Strategy, Revenue, and Growth
Unlock the full Business Model Canvas for Senseonics Holdings, Inc. and see how its continuous glucose monitoring strategy creates value, builds partnerships, and reaches patients and providers. This concise, professionally written canvas helps you understand the company’s revenue logic, cost structure, and growth levers. Perfect for investors, analysts, and strategists who want the full picture.
Partnerships
Ascensia Diabetes Care commercial partnership
Ascensia Diabetes Care has been the core commercial partner for Eversense, backing sales, marketing, and payer access while Senseonics focuses on product development. Its reach helps expand physician and patient adoption beyond Senseonics’ own field team, especially for the 365-day Eversense CGM.
University Hospitals Accountable Care Organization
Senseonics’ collaborative agreement with University Hospitals Accountable Care Organization helps support care delivery and clinical adoption inside an integrated health system, which matters in a U.S. diabetes market of about 38.4 million people. It also gives the Eversense CGM a real-world setting to prove value in day-to-day diabetes management and care coordination.
Global distributors in the US EMEA region
Senseonics reaches patients through distributors across the U.S., Europe, the Middle East, and Africa, so it can expand coverage without building a direct sales force in every market. In FY2024, the Company reported $22.1 million of revenue, and this channel model helps scale Eversense adoption while keeping fixed costs lower than a fully owned field network.
Strategic fulfillment partners
Strategic fulfillment partners move Senseonics Holdings, Inc. devices from production to clinics and patients, handling orders, warehousing, and last-mile delivery. That matters because Eversense depends on recurring sensor and accessory supply, including 90-day and 365-day sensor cycles, so any delay can hit treatment continuity and revenue conversion.
- Order handling for clinics and patients
- Logistics for recurring sensor supply
- Delivery execution for ongoing use
Healthcare providers and implanting clinics
Physicians and implanting clinics are core partners in Senseonics Holdings, Inc.'s Eversense model because they perform the in-office insertion and removal of the under-the-skin sensor. The current Eversense 365 system is designed for up to 365 days of wear, so one trained clinic can support a full year of monitoring plus replacement care.
- Insert and remove the sensor in office
- Drive adoption through patient training
- Support retention over 365-day wear
Senseonics Relies on Key Partners to Drive Eversense Sales and Adoption
Senseonics Holdings, Inc. depends on Ascensia Diabetes Care for Eversense sales, payer access, and market reach, while clinicians and implanting clinics handle insertion and removal of the 365-day sensor. In FY2024, Senseonics Holdings, Inc. reported $22.1 million of revenue, so these partners are central to adoption and repeat use.
| Partner | Role | Value |
|---|---|---|
| Ascensia Diabetes Care | Commercial launch | Sales and payer access |
| Clinics | Implant care | 365-day sensor use |
| Distributors | Market reach | U.S., EMEA coverage |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Senseonics Holdings, Inc., mapping its CGM value proposition, customers, channels, partners, costs, and revenue streams.
Customizable Excel Spreadsheet
Quickly spot how Senseonics eases diabetes management pain points in one clear, editable business model snapshot.
Reference Sources
Provides a traceable source trail for Senseonics Holdings, Inc., strengthening credibility and helping investors verify key assumptions fast.
Activities
CGM product development
Senseonics Holdings, Inc. focuses CGM product development on its implantable Eversense platform, including sensor performance, transmitter design, and app features. The 365-day Eversense CGM, FDA-approved in 2024, makes long-duration monitoring the core product edge, so this activity drives both retention and future upgrades.
Regulatory and clinical evidence generation
Senseonics Holdings, Inc. must keep funding clinical studies and FDA submissions because CGM access depends on proof of safety and accuracy; its Eversense 365 system is built around long-duration wear and new evidence generation to support approvals and reimbursement. In 2025, this work stays central as one extra regulatory clearance can open large new patient and payer markets.
Manufacturing and quality control
Senseonics runs manufacturing for its implantable CGM sensors and system parts, and the company’s Eversense 365 platform is designed for up to 365 days of wear, so batch consistency matters. In a Class III diabetes device, tight quality control helps protect patient safety and long-term sensor reliability across the full wear period.
Commercialization and market access
Senseonics’ commercialization is partner-led, so market access depends on distribution reach, provider training, and payer coverage. Its Eversense 365 is the first and only 365-day CGM sensor, which helps sales teams prove value to clinicians and insurers in a market where familiarity and reimbursement still shape adoption.
Commercial work centers on provider education, payer engagement, and demand generation, since longer wear can lower insertions to 1 per year and support better economics versus shorter-wear sensors.
- Partner sales model
- Expand reimbursement
- Train providers
- Engage payers
- Drive demand
Post-market customer support
Senseonics Holdings, Inc. uses post-market customer support to keep patients and providers on track after device placement, with app help, troubleshooting, and day-to-day usage guidance. This matters because Eversense 365 offers 365-day wear, so steady support helps users stay adherent and keep the system in use longer.
- App setup and usage help
- Device troubleshooting after implant
- Ongoing guidance for adherence
Senseonics Bets on Eversense 365, FDA Progress, and Partner-Led Growth
Senseonics Holdings, Inc.'s key activities are CGM R&D, FDA/regulatory work, and Class III sensor manufacturing for Eversense 365, the 365-day implantable CGM. In 2025, the company also focused on partner-led commercialization, provider training, and payer reimbursement to expand access.
| Key activity | 2025 signal |
|---|---|
| R&D | 365-day Eversense platform |
| Regulatory | FDA support |
| Commercial | Partner-led sales |
What You See Is What You Get
Business Model Canvas
This Senseonics Holdings, Inc. Business Model Canvas preview is a live view of the exact document you’ll receive after purchase. It is not a sample or placeholder—what you see here is the same professionally formatted file included in your download. Once purchased, you’ll get full access to this identical document, ready to edit, present, or share.
Resources
Eversense and Eversense XL technology
Senseonics Holdings, Inc.’s core IP is its implantable CGM platform: a small under-the-skin sensor, a detachable rechargeable transmitter, and a mobile app. Eversense 365 is cleared for up to 365 days of wear, while Eversense XL offered up to 180 days, giving the Company a clear edge versus typical 10- to 14-day external CGM systems.
Patent portfolio and know-how
Senseonics relies on its patent portfolio and medical-device know-how to protect the Eversense 365, a 365-day implantable CGM, and the system design behind its implantable sensing platform. That IP helps keep rivals from copying the core technology and supports a defensible position in CGM, where Senseonics posted $24.8 million in revenue in 2024.
Regulatory approvals and clinical data
Senseonics Holdings, Inc. key resources are its FDA market authorization and clinical data for Eversense E3, the 365-day implantable CGM approved in 2024 for adults with diabetes. This evidence base supports commercialization in regulated device markets and helps build trust with physicians, payers, and patients.
Commercial partner network
Senseonics Holdings, Inc.'s commercial partner network is a core resource because its distributor and fulfillment partners extend reach across the U.S. and Europe without a fully direct sales model. This lowers the need for a large in-house field force and helps scale access for Eversense while keeping operating costs more variable than fixed.
- Extends market reach through partners
- Supports leaner, scalable commercialization
- Reduces need for direct sales footprint
Medical device expertise and headquarters base
Senseonics Holdings, Inc. is based in Germantown, Maryland, and its key resources are deep diabetes-tech know-how, implantable-device engineering, and regulated manufacturing discipline. That internal base matters because Eversense 365, its 1-year continuous glucose monitor, depends on tight product support and ongoing innovation, not just outsourced production.
- HQ in Germantown, Maryland
- Eversense 365 drives support needs
- In-house skills protect quality and compliance
Senseonics’ Core Assets Power Its Eversense 365 Growth Story
Senseonics Holdings, Inc.’s key resources are its implantable CGM IP, FDA-cleared Eversense 365 platform, and diabetes-tech know-how. Its partner-led commercial model and regulated manufacturing base support scale, while 2024 revenue was $24.8 million.
| Resource | Why it matters |
|---|---|
| Eversense 365 | 365-day wear |
| IP and patents | Defends core tech |
| Partners | Extends reach |
Value Propositions
Up to 6 months of continuous glucose monitoring
Senseonics Holdings, Inc. offers implantable Eversense CGM systems that can track glucose continuously for up to 180 days, cutting sensor swaps to about 2 times a year versus weekly wearables. That longer wear can mean fewer interruptions, less skin irritation, and steadier adherence for patients managing diabetes.
Implantable under-the-skin sensor
Senseonics Holdings, Inc. offers an implantable under-the-skin sensor that stays hidden and monitors glucose continuously for up to 365 days, unlike patch-style CGMs worn on the skin. This discreet design cuts visible hardware on the body and gives users a different daily experience, with fewer device changes and less wear-time friction.
Detachable rechargeable smart transmitter
Senseonics Holdings, Inc.'s detachable rechargeable smart transmitter sits on the skin, can be removed and reattached, and works with an implanted sensor that can last up to 365 days. In trials, the Eversense 365 system delivered a mean absolute relative difference of about 8.5%, giving users a long-wear option with less daily hassle.
Mobile app based glucose tracking
Senseonics Holdings, Inc. uses a mobile app to show real-time glucose data, giving patients live visibility for day-to-day self-management. The Eversense system’s 365-day sensor and app-based alerts turn digital access into a core value driver, helping people spot trends faster and act sooner.
- Real-time glucose tracking in one app
- 365-day sensor supports long use
- Alerts help self-management decisions
Real time diabetes management support
Senseonics Holdings, Inc. gives people with diabetes continuous glucose data so they can react faster to highs and lows. Its Eversense 365 system delivers up to 365 days of monitoring, which can support quicker treatment choices and more confidence in daily control for patients and providers.
- Up to 365 days of monitoring
- Faster glucose-change response
- Better daily treatment decisions
365-Day CGM, 8.5% MARD: Senseonics’ Long-Wear Edge
Senseonics Holdings, Inc. sells a long-wear implantable CGM: Eversense 365 monitors glucose for up to 365 days, with a removable smart transmitter and app alerts that reduce wear-time friction and support faster self-management. In trials, Eversense 365 posted about 8.5% MARD, giving patients and providers a long-duration option with solid accuracy.
| Value | Metric |
|---|---|
| 365 days | Sensor wear |
| 8.5% | MARD |
Customer Relationships
Provider training and onboarding
Senseonics’ customer relationship is hands-on: clinicians must be trained to implant and manage Eversense, which uses a 180-day sensor and starts with an in-office procedure. Onboarding helps reduce placement mistakes and supports follow-up care, so it is central to adoption and safe use of a product that depends on correct procedure delivery.
Patient education and support
Senseonics Holdings, Inc. relies on patient education to help users manage the app, handle the transmitter, and keep up with daily monitoring for its 365-day Eversense CGM. Clear support lowers setup friction and helps patients fit the device into routine life, which matters for long-term adoption.
Distributor and account management
Senseonics manages distributor and strategic partner accounts with close control of forecasts, supply, and market coverage, which helps keep Eversense available where it is approved. In its latest 2025 filings, the company remained a low-revenue commercial stage business, so disciplined account management is key to matching limited inventory with partner demand.
Clinical and reimbursement support
Clinical and reimbursement support helps Senseonics Holdings, Inc. turn physician interest into paid starts, because CGM uptake often stalls at prior authorization, benefit checks, and coding. In a payer-scrutinized market, guiding clinics and patients through coverage steps can lift conversion and lower drop-off after prescription.
- Shortens insurance approval time
- Reduces patient setup friction
- Supports clinic reimbursement confidence
Ongoing technical assistance
Senseonics Holdings, Inc. needs ongoing technical assistance because users and providers may need device troubleshooting and app/software support after implant. Staying reachable after sale helps protect confidence in Eversense and supports continued use, which matters in a market where CGM adoption keeps rising and service quality can sway renewals.
- Fix device and app issues fast
- Keep users confident after sale
- Support continued system use
Hands-On Support Drives Senseonics Prescriptions
Senseonics Holdings, Inc. keeps customer ties hands-on: clinicians need training for Eversense implant and follow-up, while patients need clear support for app use, transmitter handling, and daily monitoring. In 2025, the company stayed a low-revenue commercial-stage business, so payer help, technical support, and partner account care remain key to converting prescriptions into paid starts.
| Customer relationship lever | Key data |
|---|---|
| Implant training | 180-day sensor; in-office start |
| Patient support | 365-day Eversense CGM guidance |
| Commercial scale | Low revenue in 2025 filings |
Channels
Healthcare providers
Healthcare providers are the main adoption gate for Senseonics Holdings, Inc.: they screen eligible patients, implant and remove the Eversense sensor, and drive repeat use. With Eversense E3 offering 180-day wear and the Eversense 365 reaching 1-year wear, provider access stays the key channel in a device model where one trained clinician can influence many patient starts.
Distributor network
Senseonics uses a distributor network in multiple regions to sell Eversense, including the 365-day CGM system. This model lets the Company scale internationally with local market support, while distributors drive sales execution, reimbursement access, and market penetration.
Strategic fulfillment partners
Strategic fulfillment partners handle logistics and last-mile delivery for Senseonics Holdings, Inc.'s Eversense 365 system, helping providers and patients get the 365-day sensor and supplies on time. This channel supports recurring revenue by keeping replacement and replenishment flows steady, with delivery performance tied directly to continued patient use and provider trust.
Mobile application
Senseonics Holdings, Inc.’s mobile application is a direct digital channel to end users, giving real-time glucose data and alerts after implantation. With Eversense E3, the system supports up to 180 days of continuous wear, so the app helps keep daily engagement high between clinic visits.
The channel improves user experience by making glucose trends easy to check, share, and act on in daily life. It also supports the core revenue model: as of 2025, Senseonics reported net revenue of about $22.6 million, and app-led retention helps protect recurring sensor demand.
- Direct access to glucose data
- Supports daily user engagement
- Strengthens post-implant experience
Clinical and health system relationships
Integrated health systems and ACOs can speed Senseonics Holdings, Inc. adoption because they let one clinical standard reach many sites at once, which supports repeat use and easier training. In 2025, this channel mattered because Eversense remained a long-wear CGM used in organized care settings, where protocol-driven follow-up can widen deployment.
- Standardizes care across sites
- Supports repeat prescribing
- Opens broader deployment pathways
Senseonics’ Channel Mix Drives Eversense Growth
Senseonics Holdings, Inc. relies on clinicians and training sites as the main channel for Eversense starts, implant, and removal, while distributors and fulfillment partners extend reach in local markets and keep sensors moving. The mobile app keeps users engaged between visits, and this channel mix supported about $22.6 million in net revenue in 2025.
| Channel | Role |
|---|---|
| Providers | Start, implant, remove |
| Distributors | Market reach |
| App | Daily use |
Customer Segments
Adults with diabetes using CGM
Adults with diabetes using CGM are the core end users: the IDF estimates 589 million adults (20-79) lived with diabetes in 2024, and many need live glucose data to manage daily dosing, food, and activity. Senseonics Holdings, Inc.'s Eversense 365 offers up to 365 days of wear, which fits users who value long-duration monitoring and fewer sensor changes.
Insulin-treated patients
Insulin-treated patients are Senseonics Holdings, Inc.’s core users because they need frequent glucose visibility to catch highs and lows fast. The Eversense 365 CGM, cleared for up to 365 days of wear, fits this group well by reducing fingersticks and giving long-term, real-time data for daily insulin decisions.
Endocrinologists and diabetes specialists
Endocrinologists and diabetes specialists are Senseonics Holdings, Inc.'s key prescribers: they recommend the CGM, perform or refer implant procedures, and drive patient adoption. Their clinical endorsement matters because Eversense 365 is the first and only FDA-approved 365-day implantable CGM, up from the prior 180-day system, so specialist trust directly shapes use.
Integrated delivery networks and ACOs
Integrated delivery networks and ACOs are institutional buyers that care about lower total cost, tighter care coordination, and better diabetes outcomes. Senseonics fits this segment with Eversense 365, a 365-day implantable CGM, and its University Hospitals ACO relationship shows how health systems can adopt the platform for value-based care.
- Buyers want outcome gains and workflow fit
- ACO deals can influence broader system adoption
- 365-day wear supports long-term management
International distributors and channel partners
International distributors and channel partners are a commercial customer segment in Senseonics Holdings, Inc.'s go-to-market model; they buy, stock, and move Eversense products into local markets, so their execution directly drives geographic reach and sensor sales volume. In 2025, this channel stayed important as Senseonics pushed wider commercialization of its longer-duration CGM system.
- Local market access
- Inventory and demand flow
- Sales scale depends on partner execution
Senseonics Targets a Huge Diabetes Market with 365-Day CGM
Senseonics Holdings, Inc. serves adults with diabetes, especially insulin users, and the physicians who prescribe CGM; IDF said 589 million adults had diabetes in 2024, and Eversense 365 fits users who want fewer sensor changes. Health systems and distributors are the other key segments, because they drive access, reimbursement, and local sales scale.
| Segment | Why it matters | Key number |
|---|---|---|
| Adults with diabetes | Core CGM users | 589M |
| Physicians | Prescribe and support use | 365-day wear |
| Health systems/distributors | Drive access and volume | Channel scale |
Cost Structure
Research and development spend
Senseonics Holdings, Inc. must keep spending on research and development to improve its implantable CGM platform, with costs tied to engineering, software, sensor design, and product iteration. This spend is critical because diabetes tech changes fast, and steady innovation is what keeps Senseonics competitive.
Clinical trials and regulatory costs
Clinical trials and regulatory work are a major fixed cost for Senseonics Holdings, Inc.; in 2024 it spent $25.2 million on research and development, which includes studies, submissions, and compliance tied to Eversense approvals. This spend is not one-time: FDA post-market work, label updates, and reimbursement evidence keep running after launch, because payer and regulator decisions depend on proof.
Manufacturing and quality assurance
Manufacturing Senseonics Holdings, Inc.’s implantable sensor and removable transmitter is cost-heavy because each Eversense system must be built under controlled medical-device processes, with the 365-day sensor adding specialized materials and tight process control. Quality assurance is non-negotiable in patient care, so inspection, traceability, and validation lift overhead but help protect reliability and reduce clinical risk.
Sales, marketing, and partner support
Sales, marketing, and partner support are a key cash use for Senseonics Holdings, Inc., because Eversense needs provider training, payer access work, and distributor help before revenue can scale. In a long-sales-cycle market, these costs are tied directly to demand creation and wider clinic use.
- Provider education drives adoption
- Market access supports reimbursement
- Distributor support widens reach
- Long cycles delay revenue payback
General administrative and logistics costs
Senseonics Holdings, Inc. carries general administrative and logistics costs to run headquarters, meet FDA and regional compliance needs, and move recurring Eversense components; its 180-day sensor model makes fulfillment a repeat task, not a one-time sale. These costs stay important because the business still needs sales, quality, and support coverage across markets while it scales revenue from each replacement cycle.
- HQ, legal, and compliance overhead
- Repeat logistics for 180-day sensors
- Regional support for sales and service
Senseonics Faces Heavy R&D and Commercial Cost Pressures
Senseonics Holdings, Inc. keeps cost pressure high because Eversense depends on R&D, regulatory work, and clinical evidence; 2024 research and development spend was $25.2 million. Manufacturing, provider training, and payer access also add fixed and repeat costs, since each sensor cycle needs quality control, logistics, and market support.
| Cost item | Latest figure |
|---|---|
| Research and development | $25.2 million in 2024 |
| Core drivers | Trials, FDA work, manufacturing, support |
Revenue Streams
CGM system product sales
Senseonics’ main commercial revenue comes from Eversense CGM system sales, including the implantable sensor, transmitter, and related components. This product line remains the core of its business model, with FY2025 revenue still driven by system placements and recurrent replacement sales.
Recurring sensor replacement sales
Senseonics Holdings, Inc.’s implantable Eversense sensor has a limited wear life of up to 180 days in the U.S. and up to 365 days in some markets, so each implant creates a built-in replacement cycle. That makes recurring sensor sales structurally important: every sensor that reaches end of life must be replaced to keep the patient on therapy.
Transmitter and accessory sales
Transmitter and accessory sales add recurring revenue after the implant, since each rechargeable transmitter and its parts are replaced or refreshed over time. In Senseonics Holdings, Inc.’s 2024 filings, total revenue was about $24 million, and this stream helps keep users engaged with the Eversense system beyond the first procedure.
International distributor sales
Senseonics Holdings, Inc. earns international distributor sales by shipping Eversense through regional partners, so it can monetize Europe, the Middle East, and Africa without a fully direct-sales model. This widens reach and lowers local go-to-market costs, while distributor-led markets have been a key path for EMEA expansion since Eversense approvals there.
- Regional partners sell in EMEA
- Expands access beyond direct sales
- Supports lower local operating cost
Commercial agreements and partner-linked sales
Senseonics Holdings, Inc. monetizes through commercial partnerships, led by partner-linked sales that turn clinical demand for Eversense into product movement. In 2025, its model still depended on partner reach for scale and market access, which is why collaboration-driven sales matter for penetration and recurring revenue.
- Partner sales convert demand into shipments
- Commercial deals expand market reach
- Scale depends on partner execution
Senseonics Revenue Hinges on Recurring Eversense Sales
Senseonics Holdings, Inc. Revenue Streams stay concentrated in Eversense sales: implantable sensors, transmitters, and accessories, with recurring replacement demand built into the 180-day U.S. wear cycle and longer ex-U.S. use. FY2024 revenue was about $24 million, and FY2025 still depended on partner-led shipments and repeat sales.
| Stream | Role |
|---|---|
| Sensor sales | Core recurring revenue |
| Transmitter/accessories | Post-implant repeat sales |
| Distributor sales | EMEA market access |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.